STAT Stitch Deep Dive Podcast Beyond The Bedside

STAT Stitch Deep Dive Podcast Beyond The Bedside

por Regular Guy

Cursos Ciencias de la Vida

Temporada 7

CC Pharm [RSI] | Succinylcholine

Succinylcholine is a short-acting, depolarizing neuromuscular blocking agent (NMBA) used as an adjunct to general anesthesia to facilitate tracheal intubation and provide skeletal muscle relaxation. Applying the 80/20 rule, the core clinical essence of succinylcholine centers on its rapid mechanism, critical safety warnings, and precise dosing. 1. Core Mechanism & Pharmacokinetics (The "20%" Driving Action) Mechanism: Succinylcholine competes with acetylcholine (ACh) at cholinergic receptors on the motor end-plate, depolarizing the membrane. Resistant to acetylcholinesterase, it remains bound to inhibit repolarization, causing transient muscle fasciculations followed by flaccid paralysis. Paralysis Order: Affects facial and glottis muscles first, then intercostals, diaphragm, and other skeletal muscles. Recovery occurs in the reverse order. Pharmacokinetics: Highly ionized with low lipid solubility, it distributes rapidly in extracellular space. It is hydrolyzed by plasma cholinesterase to inactive metabolites. Prolonged Blockade: Decreased plasma cholinesterase activity—due to genetics, liver/renal dysfunction, pregnancy, burns, or drugs (e.g., oral contraceptives)—prolongs neuromuscular blockade. 2. Boxed Warnings & Life-Threatening Risks (Critical Safety "80%") Severe Hyperkalemia: Contraindicated after the acute phase of major burns, multiple trauma, skeletal muscle denervation, or upper motor neuron injury. It can trigger severe hyperkalemia, peaking 7 to 10 days post-injury, causing cardiac arrest. Avoid if baseline potassium is > 5.5 mEq/L. Pediatric Safety: Contraindicated in patients with skeletal muscle myopathy (e.g., Duchenne's). Reserve pediatric use for emergency intubation due to risks of rhabdomyolysis and sudden hyperkalemic cardiac arrest (often presenting as peaked T-waves). Malignant Hyperthermia (MH): Contraindicated in patients with genetic susceptibility (RYR1 or CACNA1S variants). Inhalation anesthetics compound this risk. Continuous ETCO2 and temperature monitoring are vital for early recognition. 3. Key Clinical Dosing & Administration Rapid-Sequence Intubation (RSI):Adults: 1.5 mg/kg IV (onset ~1 min). Pediatrics (2-17 years): 1 to 1.5 mg/kg IV. Infants & Neonates: 2 mg/kg IV. Non-Emergent Intubation:Adults: 0.6 mg/kg IV (range: 0.3 to 1.1 mg/kg). Intramuscular (IM) Backup: Used if IV access is unavailable. Adults: 3 to 4 mg/kg (Max: 150 mg); Infants/Children: 4 to 5 mg/kg IM. Onset is 2 to 5 minutes. Incompatibilities: Succinylcholine is acidic (pH 3 to 4.5); do not mix with alkaline solutions (pH > 8.5).

CC PHARM [RSI] | Vecuronium

Vecuronium is an intermediate-acting, nondepolarizing neuromuscular blocking agent used for skeletal muscle relaxation during surgery, mechanical ventilation, and endotracheal intubation, including rapid-sequence intubation (RSI). 1. Critical Safety & Boxed Warning (The Vital 20%) Respiratory Paralysis: Causes respiratory paralysis (potentially fatal). Administer only by experienced clinicians in settings with immediate intubation, ventilation, oxygen, and reversal agents. Induction Prerequisite: To prevent extreme distress, vecuronium must only be administered after unconsciousness is induced with adequate amnesia, sedation, and analgesia. Storage Warning: Due to risk of fatal accidental administration, store vials with cap/ferrule intact and separated from other drugs to prevent selection errors. 2. Mechanism of Action & Pharmacokinetics Mechanism: Competes with acetylcholine (ACh) for receptors at the motor end-plate. Paralysis progresses predictably: fine muscles (eyes, face, neck) first, then limbs, chest, abdomen, and lastly the diaphragm. Recovery occurs in reverse order. Onset & Duration: IV administration acts within 1 minute, peaks at 3 to 5 minutes, and lasts 25 to 40 minutes. Metabolism & Elimination: 60% to 80% protein-bound. Active 3-desacetyl metabolite has 50% to 70% potency of parent compound. Elimination half-life: 65 mins (infants), 41 mins (children), and 65 to 75 mins (adults). 3. Core Clinical Dosing Rapid-Sequence Intubation (RSI):Adults: 0.1-0.2 mg/kg IV (onset 2-4 mins). Pediatrics (7 weeks to 17 years): 0.15-0.2 mg/kg IV (onset 2.5-3 mins). Neonates (<7 weeks): 0.1 mg/kg IV (onset 2.5-3 mins). Mechanical Ventilation & Surgery:Adults: 0.08-0.1 mg/kg initial IV bolus, then 0.01-0.015 mg/kg every 12-15 mins as needed, or continuous infusion of 0.8-1.7 mcg/kg/min. Defasciculation: 0.01 mg/kg IV given 1-3 mins before succinylcholine in adults. Rare in pediatrics. 4. Reconstitution & Stability Reconstitution: Add 10 or 20 mL of Bacteriostatic Water to 10 or 20 mg vials (1 mg/mL). For neonates, use Sterile Water to avoid benzyl alcohol toxicity. Storage: Bacteriostatic water reconstitution lasts 5 days (room temp/refrigerated); Sterile Water is single-use and discarded within 24 hours. Do not mix with alkaline solutions. 5. Monitoring & Adverse Effects Monitoring: Use a peripheral nerve stimulator to monitor response (target: 1 to 2 twitches). Adverse Reactions: Major risks include bronchospasm, anaphylaxis, acute myopathy, prolonged paralysis, tachycardia, and hypotension. Minimal histamine release occurs. 📊 I can generate a quick reference dosing card or a cheat sheet comparing these pediatric vs. adult infusion rates for your clinical review.

CC Pharm | Vasopressin

Vasopressin (Vasostrict) Clinical Reference 1. Action: Exogenous ADH analog. Promotes renal water reabsorption via cAMP. Directly contracts vascular smooth muscle non-adrenergically. 2. Use: Raising BP in vasodilatory shock refractory to fluids/catecholamines; post-op abdominal distention. 3. Complications: Cardiac arrest, bradycardia, MI, AFib, water intoxication, severe hyponatremia, necrosis. 4. Admin: IV infusion must go through central vein. If peripheral, use >=20G catheter & check frequently. Premixed (0.4/0.6 units/mL) needs no dilution. Dilute 20 units/mL to 0.1 or 1 unit/mL in NS/D5W. Discard after 18h room temp, 24h refrigerated. IM/SC duration is 2-8h; IO used in CPR. 5. Contraindications: No renal/hepatic adjustments needed. Caution in coronary artery disease (ischemia risk). 6. Nursing: Monitor ECG, BP, fluids, sites. For extravasation, inject 5-10 mg phentolamine directly. 7. Interactions: Muscle contraction not blocked by adrenergic blockers/denervation. No CYP450 interactions. 8. Education: ICU drug; explain central line need and to report chest pain or IV burning. 9. Evaluation: Increased MAP, catecholamine-sparing, stable sodium/osmolality. 10. Why Choose? Bypasses catecholamine resistance. Onset peaks <15 min; fades <20 min of stopping. 11. Pearls: Most Dangerous: MI, tissue necrosis. Key Lab: Serum sodium (detects hyponatremia). Antidote: Phentolamine 5-10 mg for extravasation. NCLEX/ATI: Run through central line to prevent necrosis. 12. Scenario: Septic shock patient hypotensive on norepinephrine. Adding vasopressin raises MAP, allowing down-titration of toxic catecholamines. 13. Mnemonic: Vasopressin Presses Vessels (V1 constriction) & Preserves Volume (V2 reabsorption). THE 20% I ABSOLUTELY NEED TO KNOW Catecholamine-Saver: Works on non-adrenergic receptors, maintaining potency in severe acidotic shock where catecholamine receptors are down-regulated. Extravasation Rescue: High necrosis risk peripherally. Immediately inject 5-10 mg phentolamine to site if extravasation occurs. Water Retention: Exogenous ADH action causes renal water retention, causing dilutional hyponatremia/water intoxication. IF I REMEMBER NOTHING ELSE Direct non-adrenergic vasoconstrictor with strong catecholamine-sparing effect. IV onset peaks <15 min; pressor effects fade <20 min of stopping. Central line infusion preferred; extravasation causes severe skin necrosis. Phentolamine (5-10 mg) is the antidote for local extravasation. Conserves free water; monitor closely for hyponatremia. No hepatic or renal dosage adjustments are required.

CC Pharm | Norepinephrine

Norepinephrine (Levophed) 80/20 Summary Action & MOA: Direct α-agonist causing potent vasoconstriction. Modest β1 activity triggers cardiac stimulation at lower doses; vasoconstriction dominates at higher doses. Elevated SVR triggers reflex vagal bradycardia (slowing HR). Coronary flow increases without raising myocardial oxygen demand. Uses: First-line for septic shock, sepsis, acute hypotension, cardiogenic shock. Alternative in hepatorenal syndrome (with albumin). Complications: Tissue necrosis (extravasation), bradycardia, lactic acidosis, pulmonary edema, hypertension, and local hypoxia. Administration & Dilution:Dilution: Standard: 4mg in 1,000mL. Preferred: D5W/D5NS (dextrose protects against oxidation). Saline alone stable up to 16mcg/mL, though FDA discourages. Adult standard: 16, 32, 128mcg/mL. Incompatibility: Do not mix with alkaline solutions (e.g., bicarb). Reject if pinkish/discolored or has precipitate. Route: Large vein infusion; transition to central line ASAP. Avoid leg veins in elderly. Monitoring: BP every 2 mins initially, then every 5 mins. Check site frequently for free flow/extravasation. Weaning: Reduce rate gradually; avoid abrupt withdrawal to prevent rebound hypotension. Extravasation Antidote: Infiltrate ASAP (within 12h) with phentolamine 5-10mg in 10-15mL NS. Pharmacokinetics: Onset <30s; steady-state 5 mins; duration <10 mins. Half-life ~2.4 mins; metabolized by COMT/MAO. Why Choose It? Preferred in septic shock; raises MAP/SVR with less tachycardia than dopamine, sparing oxygen demand. Final 80/20 Review The 20% to Absolutely Know:Hypovolemia First: Correct fluid deficit before starting norepinephrine. Central Line Priority: Transition to central line ASAP to mitigate necrosis risk. Phentolamine for Extravasation: Immediate local infiltration reverses ischemia. Dextrose Over Saline: Dextrose-containing diluents prevent oxidation. Incompatible with Bicarb: Inactivated in alkaline solutions. If I Remember Nothing Else: Norepinephrine is the first-line vasopressor for septic shock. With a <30s onset and 2.4m half-life, it requires continuous infusion, BP checks every 2–5 mins, and gradual weaning. Monitor the IV site continuously; treat extravasation with immediate phentolamine infiltration to prevent necrosis.

CC Pharm | Propofol

Clinical Action & Pharmacokinetics Mechanism: Propofol is an IV anesthetic/sedative that enhances GABAA currents by slowing deactivation and reducing receptor desensitization. It also inhibits NMDA glutamate receptors, depressing excitatory transmission, and exerts antiemetic effects by reducing serotonin in the area postrema. Pharmacokinetics: Follows a 3-compartment linear model. Onset is rapid (~40s) via quick blood-brain equilibration. Clearance is 23–50 mL/kg/min via hepatic conjugation to inactive metabolites excreted by kidneys. Distribution accounts for 50% of plasma decline. Infusions over 10 days accumulate in fat, extending terminal half-life to 1–3 days and delaying recovery. Critical Administration & Dosing Rules Safe Handling: It is a single-use product; maintain strict aseptic technique. Discard unused propofol or tubing within 12 hours of opening, or within 6 hours if mixed with lidocaine. Do not administer Fresenius Propoven via a microbiological filter. Induction Dosing (IV):Healthy Adults (18–64): 2 to 2.5 mg/kg IV titrated to response. Geriatric/Debilitated/ASA III/IV: 1 to 1.5 mg/kg IV. Pediatric (3–16): 2.5 to 3.5 mg/kg IV. Maintenance & ICU Sedation:Anesthesia Maintenance: 50 to 100 mcg/kg/min continuous IV infusion after a 150–200 mcg/kg/min loading phase. ICU Sedation (Ventilated Adults): Start at 5 mcg/kg/min; titrate by 5–10 mcg/kg/min every 5–10 minutes (usual range: 5–50 mcg/kg/min). Do not exceed 4 mg/kg/hour unless benefits outweigh risks. Discontinuation: Avoid abrupt withdrawal to prevent rapid awakening, anxiety, and ventilator resistance; maintain light sedation until 10–15 minutes before extubation. Pain Reduction: Administer via larger veins, or add IV lidocaine (up to 20 mg per 200 mg propofol) immediately before injection. Major Safety Warnings & Complications Provider Requirements: Administer only by clinicians trained in general anesthesia or critical care, with immediate access to airway, ventilation, and resuscitation equipment. Lock/manage inventory to prevent diversion. Adverse Reactions:Cardiovascular & Respiratory: Hypotension is highly common (3% to 26%). Other risks include bradycardia (1% to 3%), apnea (1% to 3%), respiratory depression, hypoxia, and pulmonary edema. PRIS: Prolonged, high-dose infusions for ICU sedation are associated with Propofol-Related Infusion Syndrome (PRIS), causing fatal metabolic derangements and organ failure. EUA Warning: Fresenius Propoven 2% is double the strength (20 mg/mL) of standard FDA-approved 1% (10 mg/mL). Exercise extreme caution with pump settings to prevent overdose.

CC Pharm | Epinephrine

Epinephrine is a potent, nonselective adrenergic agonist acting on alpha-1, alpha-2, beta-1, and beta-2 receptors. This high-yield 80/20 summary covers the essential clinical and exam concepts: 1. Expected Pharmacological Action & Mechanism Alpha-1 activation causes arteriolar vasoconstriction. Beta-1 activation induces positive inotropic and chronotropic responses, increasing cardiac workload and coronary vasodilation. Beta-2 activation drives bronchodilation, skeletal muscle vasodilation, and hepatic glycogenolysis. Alpha-2 activation inhibits insulin release and provides negative feedback on norepinephrine. Actions are mediated by cyclic AMP (increased by beta, decreased by alpha). 2. Clinical Indications & Route Optimization Anaphylaxis: Drug of choice. Intramuscular (IM) injection in the anterolateral thigh (vastus lateralis) is preferred because absorption is rapid and complete. Subcutaneous (SQ) absorption is delayed and variable, making it not routinely recommended. Cardiac Arrest: Administer 1 mg IV or IO every 3 to 5 minutes. Do not interrupt CPR to administer. Flush with 0.9% NaCl to promote central entry. Hemodynamic Support: Continuous IV infusion at 0.01 to 2 mcg/kg/min. Low doses (<0.3 mcg/kg/min) favor beta-effects (tachycardia, inotropy, decreased SVR), while higher doses (>0.3 mcg/kg/min) cause alpha-vasoconstriction. Endotracheal (ET): Used only if IV/IO is delayed. Requires higher doses (e.g., 2 to 2.5 mg in adults) and is associated with lower drug levels and survival. 3. Safety, Administration & Nursing Interventions Extravasation Antidote: Extravasation causes severe ischemia and tissue necrosis. Avoid peripheral leg veins in the elderly. Immediately infiltrate the cold, pale area with phentolamine (5 to 10 mg in 10 to 15 mL saline for adults). Incompatibilities: Epinephrine is inactivated in alkaline solutions and is incompatible with sodium bicarbonate. Protect from light; discard if cloudy, pinkish, or brownish. Metabolic Tracking: Monitor for transient hyperkalemia followed by hypokalemia (due to potassium uptake into skeletal muscles), and hyperglycemia (due to insulin inhibition and glycogenolysis). Complications: Watch for severe reactions including stroke, myocardial infarction, ventricular fibrillation/tachycardia, pulmonary edema, and severe hypertension.

CC Pharm | Amiodarone

Amiodarone (Cordarone) Clinical 80/20 Summary 1. Mechanism & Physiological Effects (The 20% Science) Multiclass Action: Class III antiarrhythmic (potassium blocker delaying phase 2/3 repolarization and prolonging refractory period). Also exhibits Class I (sodium blockade slowing phase 0), Class II (noncompetitive alpha/beta-blockade), and Class IV (calcium blockade) properties. Hemodynamics: Relaxes smooth/cardiac muscle, decreasing peripheral/coronary vascular resistance and afterload, reducing myocardial oxygen demand (MVO2). 2. Clinical Uses & Key Dosing Ventricular Arrhythmias (ACLS): For pulseless VF/VT: 300 mg IV/IO push, then 150 mg if refractory. Stable VT / Wide-Complex Tachycardia: 150 mg IV over 10 min, then 1 mg/min for 6 hours, then 0.5 mg/min maintenance. Atrial Fibrillation/Flutter (Off-Label): Rate control and conversion. Oral Dosing: Slow absorption and massive tissue distribution require large loading (800–1600 mg/day for 1–3 weeks) before maintenance of 200–400 mg/day. 3. Critical Toxicities & Warnings (The High-Risk 20%) Pulmonary Toxicity: Fatal pneumonitis or alveolar/pulmonary fibrosis (up to 17% incidence; 10% mortality). Monitor baseline and regular PFTs and chest X-rays. Hepatotoxicity: Can cause severe liver injury. Monitor transaminases; hold or reduce dose if LFTs exceed 3x upper limit of normal. Thyroid Dysfunction: Amiodarone is 37% iodine by weight and blocks T4-to-T3 conversion. Can cause hypo- or hyperthyroidism (thyrotoxicosis). Monitor TSH. Cardiotoxicity: Bradycardia, AV blocks, and QT prolongation leading to Torsade de Pointes. Contraindicated in sick sinus syndrome and 2nd/3rd-degree block without a pacemaker. Ocular/Dermatologic: Corneal microdeposits (common), photosensitivity, and blue-gray skin discoloration. 4. Nursing & Administration Pearls Infusion Safety: Concentrations >2 mg/mL cause severe phlebitis; use a central line for infusions >1 hour. Always use an in-line filter and volumetric pump. Incompatibility: Adsorbs to PVC (dosing accounts for this) and leaches toxic DEHP plasticizers from PVC tubing. Use glass or polyolefin containers for infusions >2 hours. Pharmacokinetics: Highly lipophilic; volume of distribution is ~70 L/kg. Terminal half-life averages 53 days (range 26–107 days). Effects and interactions (inhibits CYP3A4, CYP2C9, P-gp) persist for months after stopping. Client Education: Take consistently with/without food. Report new dyspnea or cough immediately. Wear sunscreen. Follow up for ophthalmic, thyroid, and liver testing.

CC Pharm | Piperacillin/ Tazo [Zosyn]

Zosyn (Piperacillin/Tazobactam) 80/20 Clinical Summary Core Classification & Mechanism Drug Class: Zosyn is an injectable combination of piperacillin (extended-spectrum penicillin) and tazobactam (beta-lactamase inhibitor). Bactericidal Action: Piperacillin binds to penicillin-binding proteins (PBPs), inhibiting cell wall synthesis and causing autolysin-mediated lysis. Beta-Lactamase Protection: Tazobactam is an irreversible inhibitor of beta-lactamases (Sykes types II–V, staphylococcal penicillinase, and ESBLs), shielding piperacillin. Pharmacodynamics: Exhibits time-dependent (concentration-independent) killing, relying on time free drug levels remain above the pathogen's MIC. Pharmacokinetics & Delivery Administration: Given via IV infusion over at least 30 minutes or via extended (4-hour) / continuous (24-hour) infusions. It is not FDA-approved for IV push. Distribution: Widely distributed in tissues (50–100% of plasma); both drugs are ~30% protein-bound. Elimination: Cleared unchanged in urine (68% piperacillin, 80% tazobactam) via tubular secretion/glomerular filtration. Half-life is 0.7–1.5 hours in normal renal function. High-Yield Indications & Adult Dosing Skin/Skin Structure: 3.375 g IV every 6 to 8 hours (for 5 to 14 days). Intra-abdominal: 3.375 g IV every 4 to 6 hours or 4.5 g IV every 6 hours. Nosocomial Pneumonia: 4.5 g IV every 6 hours (for 7 to 14 days). Sepsis/Bacteremia & Febrile Neutropenia: 4.5 g IV every 6 hours. Renal & Hepatic Adjustments Hepatic Impairment: No dose adjustment needed. Renal Impairment (Conventional Adult Dosing):CrCl > 40 mL/min: No adjustment. CrCl 20 to 40 mL/min: Nosocomial pneumonia reduced to 3.375 g every 6 hours; other indications reduced to 2.25 g every 6 hours. CrCl < 20 mL/min: Nosocomial pneumonia reduced to 2.25 g every 6 hours; other indications reduced to 2.25 g every 8 hours. Hemodialysis: Max 2.25 g every 8 hours (pneumonia) or 12 hours (others); give a 0.75 g to 1.125 g supplemental dose post-dialysis as 30–40% is cleared. Key Safety & Adverse Reactions Common: Diarrhea (11.3–20.0%), headache, nausea (5.8–6.9%), and constipation (7.7–8.4%). Severe Risks: Anaphylactic shock, acute renal failure, seizures, and C. difficile-associated diarrhea. Hematologic Warnings: Leukopenia, thrombocytopenia, platelet dysfunction, and prolonged bleeding times. Cutaneous Reactions: Stevens-Johnson syndrome, TEN, and DRESS.

CC Pharm | Dopamine

Dose-Dependent Mechanism: Dopamine is a metabolic precursor to norepinephrine. Clinical effects depend entirely on the infusion rate:Low Dose (< 5 mcg/kg/min): Stimulates dopaminergic D1 and D2 receptors in renal, mesenteric, coronary, and cerebral beds, causing vasodilation and increasing blood flow. Intermediate Dose (5 to 10 mcg/kg/min): Stimulates dopaminergic and beta-1-receptors, increasing cardiac contractility, chronotropy, and mildly raising systemic vascular resistance. High Dose (> 10 mcg/kg/min): Stimulates alpha-receptors, causing potent vasoconstriction. Rates > 20 mcg/kg/min frequently cause arrhythmias or severe vasoconstriction. Key Indications: Dopamine provides hemodynamic support in distributive shock (e.g., septic, cardiogenic, anaphylactic, neurogenic), open-heart surgery, or renal failure. It is used for symptomatic bradycardia unresponsive to atropine or pacing, and post-cardiac arrest hypotension. It can provide short-term inotropic support in acute/chronic heart failure. Black Box Warning (Extravasation): Extravasation can cause severe tissue necrosis. Dopamine must be infused into a large vein (e.g., antecubital fossa). If extravasation occurs, immediately infiltrate the area with 10 to 15 mL of 0.9% NaCl containing 5 to 10 mg of phentolamine using a fine needle. The Supporting 80% (Operational Details) Administration & Incompatibilities: Correct hypovolemia before starting. Dilute concentrate in compatible solutions (e.g., 5% Dextrose, 0.9% NaCl) to 200–1,600 mcg/mL (standard adult infusions use 1,600 or 3,200 mcg/mL). It is completely inactivated in alkaline solutions; never add to Sodium Bicarbonate. Do not run dextrose-containing dopamine through the same line as blood to prevent hemolysis. Monitor urine flow, cardiac output, and blood pressure. Dosing:Adults: Initially 2 to 5 mcg/kg/min, titrating by 5 to 10 mcg/kg/min (Max: 50 mcg/kg/min). Pediatrics (Neonates to Adolescents): Initially 1 to 5 mcg/kg/min, titrating by 2.5 to 5 mcg/kg/min (Max: 15 to 20 mcg/kg/min). Pharmacokinetics: Administered via IV or intraosseously (during CPR). Onset is within 5 minutes, persisting under 10 minutes, with a 2-minute plasma half-life. It does not cross the blood-brain barrier significantly and is metabolized in liver, kidneys, and plasma by MAO and COMT. About 25% is converted to norepinephrine. Excreted in urine.

CC Pharm | Albuterol

Description & Key Indications: Albuterol is a short-acting beta-2 agonist (SABA) used as an inhaled bronchodilating agent. It treats acute bronchospasm and episodic wheezing in asthma, exercise-induced bronchospasm (EIB) prophylaxis, and serves as reliever therapy in COPD. Off-label uses include hyperkalemia, where it lowers potassium by 1–1.5 mEq/L, and managing respiratory symptoms in anaphylaxis unresponsive to epinephrine. Inhaled albuterol is preferred over oral routes due to its superior side-effect profile and faster onset. Mechanism of Action: As a racemic mixture, bronchodilation is driven by the R-isomer (levalbuterol); the S-isomer exhibits bronchoconstrictive properties in animals. Albuterol stimulates moderately selective beta-2 receptors, activating adenylate cyclase to increase intracellular cyclic AMP. This triggers protein kinase A, inhibiting myosin phosphorylation and lowering calcium to relax bronchial smooth muscle. It also inhibits mast cell degranulation and drives potassium intracellularly via the Na/K ATPase pump. Crucial Safety & Adverse Effects: Inhalation avoids many systemic issues, but severe reactions can occur, including paradoxical bronchospasm, arrhythmia, atrial fibrillation, Stevens-Johnson syndrome, and anaphylactoid reactions. Common mild-to-moderate effects include tremors (to 37.9%), infections (to 21%), headaches, rhinitis, tachycardia, palpitations, hypokalemia, and excitability. Remaining 80% (Administration, Dosages & Pharmacokinetics) Administration Techniques: Inhalation methods include metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and nebulizers. MDIs require shaking, priming, and slow inhalation, followed by a 10-second breath hold; spacers or valved holding chambers (VHC) are recommended for pediatric and uncoordinated patients. For pediatric acute asthma, MDI with a VHC is as effective as nebulization. DPIs (e.g., RespiClick) are breath-activated upon opening the cap and must remain dry at all times. Nebulized solution is delivered over 5 to 15 minutes; "blow-by" is discouraged. Dosing Standards: For acute asthma exacerbations, adults and children age 6 and older inhale 360–900 mcg via MDI every 20 minutes for the first hour, then every 1 to 4 hours as needed. EIB prophylaxis requires 180 mcg inhaled 15–30 minutes before exercise. Oral doses range from 2–4 mg 3–4 times daily, but guidelines discourage this route due to slow onset and systemic side effects. Pharmacokinetics: Inhaled albuterol works within 5–15 minutes, peaks in 0.5–2 hours, and lasts 2–6 hours, with 90% of the dose typically swallowed. Oral immediate-release onset is 30 minutes, lasting 4–6 hours, while extended-release lasts 8–12 hours. Metabolism is hepatic, and excretion is primarily renal.

25 de 34